Table 1.

Patients Characteristics.

Variables	Values
Socio-Demographics, vital signs and Comorbidities
Age (years), median (IQR)	70 (58–78)
Male, n (%)	8971 (67.1)
Body temperature, median (IQR)	36.1 (35.9–36.3)
Renal Replacement Therapy Vintage (months), median (IQR)	17.3 (5.3–59.3)
AVF vintage (months), median (IQR)	9.3 (3.7–42.7)
Diabetes mellitus, n (%)	4959 (37.1)
Complicated Diabetes, n (%)	4238 (31.7)
Biochemical parameters
Albumin (g/dL), mean (IQR)	3.9 (3.6–4.1)
C-reactive protein (mg/L), mean (IQR)	5.1 (2.1–12)
Ferritin (ng/mL), median (IQR)	391 (204–615)
Glucose (mg/dL), median (IQR)	113 (94–152)
PTH (pg/mL), median (IQR)	245 (143–392)
HD treatment parameters
Treatment time (min), median (IQR)	240 (239–242)
Ultrafiltration (L), median (IQR)	3.3 (2.8–4)
Effective blood flow (mL/min), median (IQR)	397 (357–428)
Effective processed blood volume (L), median (IQR)	95.7 (85.1–103.9)
Kt/V, mean (SD)	1.8 (0.4)
Recirculation, median (IQR)	13.9 (11.4–17.7)
Characteristics of AVF in use
Days since the last use of previous vascular access, median (IQR)	74 (38–115)
Number of vascular accesses used in the past 6 months, mean (SD)	1.3 (0.5)
Number of treatments with AVF in the past 6 months, mean (SD)	88.6 (56.3)
AVF hemodynamic properties
Dynamic venous pressure: Mean (mmHg), median (IQR)	182 (165–202)
Dynamic arterial pressure: Mean (mmHg), median (IQR)	−200 (−216–−181)
AVF failure history and previous adverse events
Number of failures: current AVF, mean (SD)	0.6 (1.5)
Days since the last failure, mean (SD)	168 (88.6)
Number of previous thrombosis, mean (SD)	0.4 (1)
Other active vascular access, mean (SD)	0.4 (0.7)
History of vascular access complications, mean (SD)	0.5 (1.4)

All variables were included in the AVF Failure Model. IQR, interquartile range; SD, standard deviation; AVF, arteriovenous fistula.